180 related articles for article (PubMed ID: 31110735)
1. Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma.
Stack A; Levy I
Clin Case Rep; 2019 May; 7(5):1003-1006. PubMed ID: 31110735
[TBL] [Abstract][Full Text] [Related]
2. Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin.
Stack A; Ali N; Khan N
J Cell Immunol; 2020 May; 2(3):80-89. PubMed ID: 32914146
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
4. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
5. Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.
Richardson K; Alrifai T; Grant-Szymanski K; Kouris GJ; Venugopal P; Mahon B; Karmali R
Mol Clin Oncol; 2017 Apr; 6(4):539-542. PubMed ID: 28413663
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
8. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.
Alderuccio JP; Desai A; Yepes MM; Chapman JR; Vega F; Lossos IS
Clin Case Rep; 2018 Apr; 6(4):634-637. PubMed ID: 29636930
[TBL] [Abstract][Full Text] [Related]
9. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.
Johnson L; O'Donoghue JM; McLean N; Turton P; Khan AA; Turner SD; Lennard A; Collis N; Butterworth M; Gui G; Bristol J; Hurren J; Smith S; Grover K; Spyrou G; Krupa K; Azmy IA; Young IE; Staiano JJ; Khalil H; MacNeill FA
Eur J Surg Oncol; 2017 Aug; 43(8):1393-1401. PubMed ID: 28596034
[TBL] [Abstract][Full Text] [Related]
10. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
Chen X; Soma LA; Fromm JR
Onco Targets Ther; 2013 Dec; 7():45-56. PubMed ID: 24379682
[TBL] [Abstract][Full Text] [Related]
14. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G
Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
16. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
[TBL] [Abstract][Full Text] [Related]
18. Stage IV Breast Implant-associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy.
Thibodeau R; Fan KL; Wehner PB
Plast Reconstr Surg Glob Open; 2019 Sep; 7(9):e2446. PubMed ID: 31942403
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
20. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis.
K Groth A; Graf R
Aesthetic Plast Surg; 2020 Feb; 44(1):1-12. PubMed ID: 31624894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
